Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

Acute myeloid leukemia

Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?

Leukemia volume 34, pages 963–965 (2020)Cite this article

Subjects

This article has been updated

To him that hath, more shall be given; and from him that hath not, the little that he hath shall be taken away.

To him that hath, more shall be given; and from him that hath not, the little that he hath shall be taken away.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 25 August 2021

    The tagging of the author names was corrected

References

  1. Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik VI, Paschka P, et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet. 2017;49:332–40.

    Article  CAS  Google Scholar 

  2. Schuurhuis GJ, Heuser M, Freeman S, Béné M-C, Buccisano F, Cloos J et al. Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party. Blood. 2018: blood-2017-09-801498.

  3. Freeman SD, Hourigan CS. MRD evaluation of AML in clinical practice: are we there yet? Hematology. 2019;2019:557–69.

    Article  Google Scholar 

  4. Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, al Hinai A, Zeilemaker A, et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N Engl J Med. 2018;378:1189–99.

    Article  CAS  Google Scholar 

  5. Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422–33.

    Article  CAS  Google Scholar 

  6. Terwijn M, van Putten WLJ, Kelder A, van der Velden VHJ, Brooimans RA, Pabst T, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31:3889–97.

    Article  Google Scholar 

  7. Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2012;119:332–41.

    Article  CAS  Google Scholar 

  8. Guénot C, Lacombe F, Allou K, Dumezy F, Feuillard J, Geneviève F, et al. Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia. Leukemia. 2019;33:1814–6.

    Article  Google Scholar 

  9. Höllein A, Jeromin S, Meggendorfer M, Fasan A, Nadarajah N, Kern W, et al. Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients. Leukemia. 2018;32:2270–4.

    Article  Google Scholar 

  10. Hoffmann H, Thiede C, Glauche I, Kramer M, Röllig C, Ehninger G, et al. The prognostic potential of monitoring disease dynamics in NPM1-positive acute myeloid leukemia. Leukemia. 2019;33:1531–4.

    Article  CAS  Google Scholar 

  11. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

    Article  Google Scholar 

  12. Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9:579–90.

    Article  CAS  Google Scholar 

  13. Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34:329–36.

    Article  Google Scholar 

  14. Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132:1703–13.

    Article  CAS  Google Scholar 

  15. Dillon R, Hills RK, Freeman SD, Potter N, Jovanovic J, Ivey A et al. Molecular MRD status and outcome after transplantation in NPM1 mutated AML: results from the UK NCRI AML17 study. Blood. 2020. https://doi.org/10.1182/blood.2019002959.

  16. Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102:865–73.

    Article  CAS  Google Scholar 

  17. Cornelissen JJ, Versluis J, Passweg JR, van Putten WLJ, Manz MG, Maertens J, et al. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years. Leukemia. 2015;29:1041–50.

    Article  CAS  Google Scholar 

  18. Leung W, Pui C-H, Coustan-Smith E, Yang J, Pei D, Gan K, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood. 2012;120:468–72.

    Article  CAS  Google Scholar 

  19. Buccisano F, Maurillo L, Piciocchi A, Del Principe MI, Picardi A, Cerretti R, et al. Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. Bone Marrow Transpl. 2017;52:473–5.

    Article  CAS  Google Scholar 

  20. Zhu H-H, Zhang X-H, Qin Y-Z, Liu D-H, Jiang H, Chen H, et al. MRD-directed risk-stratification treatment may improve outcome of t (8;21) AML in the first complete remission: results from AML05 Multicenter Trial. Blood. 2013;121:4056–63.

    Article  CAS  Google Scholar 

  21. Venditti A, Piciocchi A, Candoni A, Melillo L, Calafiore V, Cairoli R, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. 2019;134:935–45.

    Article  CAS  Google Scholar 

  22. Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncology. 2019;JCO.19.03011.

  23. Othus M, Gale RP, Hourigan CS, Walter RB. Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. Bone Marrow Transplant. 2019. https://doi.org/10.1038/s41409-019-0729-4.

  24. Butturini A, Klein J, Gale RP. Modeling minimal residual disease (MRD)-testing. Leuk Res. 2003;27:293–300.

    Article  Google Scholar 

  25. Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017;31:1482–1490.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedicine and Prevention at University “Tor Vergata”, Fondazione Policlinico Tor Vergata, Rome, Italy

    Adriano Venditti & Francesco Buccisano

  2. Haematology Research Centre, Department of Immunology and Inflammation, Imperial College London, London, UK

    Robert Peter Gale

  3. Department of Hematology, VU University Medical Centre Amsterdam, Amsterdam, Noord-Holland, The Netherlands

    Gert Ossenkoppele

Authors
  1. Adriano Venditti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Peter Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Buccisano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gert Ossenkoppele
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adriano Venditti.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Venditti, A., Gale, R.P., Buccisano, F. et al. Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?. Leukemia 34, 963–965 (2020). https://doi.org/10.1038/s41375-020-0780-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-020-0780-6

This article is cited by

Search

Advanced search

Quick links